Investing in ImmunityBio’s Growth
ImmunityBio gains $300 million in non-dilutive capital for commercialization and pipeline expansion efforts. The investment is in anticipation of potential regulatory approval of N-803 for bladder cancer and future development of more novel drugs and vaccines to fight cancer and infectious diseases.
Outsmart Your Disease®
ImmunityBio is developing immunotherapy products and cell therapies for cancer that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells.
Researching Ways to Prevent Cancer
ImmunityBio is working with the National Cancer Institute (NCI) on the largest Lynch syndrome cancer prevention study in the U.S. People with hereditary Lynch syndrome can develop colorectal cancer decades earlier than average, and have increased risk of developing other cancer types.
Testing a Better Treatment for Bladder Cancer
We reported positive results for our immune enhancer N-803 + BCG for the treatment of BCG-unresponsive NMIBC CIS, and submitted a BLA to the FDA. The user fee goal date (PDUFA) is April 23, 2024.
We are committed to increasing diversity in clinical trials
Increasing diversity and fostering inclusion among clinical trial participants ensures that trial results help reduce current disparities in healthcare.
Solutions for PatientsMany cancer therapies, including radiation therapy, chemotherapy, CAR-T therapy, and B-cell immunotherapy, severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.
Opportunities for Trial InvestigatorsThe broad therapeutic potential and demonstrated safety of ImmunityBio’s immune-enhancing IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and our next-generation adenovirus-vectored anti-cancer vaccines make them appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research. Interested clinicians and other are encouraged to contact ImmunityBio to find out how they may support discovery of future cancer treatments.
Tools for Research ScientistsOur NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.
At ImmunityBio, we envision a day when we no longer fear cancer, but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both the innate and adaptive branches of the immune system, to facilitate the attack and elimination of cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease.
Smart Therapies for Difficult Diseases®
Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.
A Robust Clinical Pipeline
We are applying our science and platforms, including the development of potential cancer vaccines, to treat cancers, as well as developing immuno- and cell therapies that we believe could sharply reduce or eliminate the need for standard high-dose chemotherapy.
Latest News & Events
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
The first 20 participants have been enrolled in an important national, multicenter trial to test whether ImmunityBio’s...
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
Patient Reported Outcomes (PROs) based on a May 16, 2022 data cutoff in the QUILT 3.032 trial indicate stability of...
American Society of Clinical Oncology’s annual meeting Date: May 31-June 4, 2024 Location: Chicago, ILbooth #27143